Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:AEGR
CUSIP00767E10
Phone+1-617-5007867
Debt
Debt-to-Equity Ratio-19.22
Current Ratio1.02
Quick Ratio0.67
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-75.07%
Return on EquityN/A
Return on Assets-29.21%
Miscellaneous
Employees318
Outstanding Shares29,540,000
Market Cap$56.69 million
Aegerion Pharmaceuticals (NASDAQ:AEGR) Frequently Asked Questions
What is Aegerion Pharmaceuticals' stock symbol?
Aegerion Pharmaceuticals trades on the NASDAQ under the ticker symbol "AEGR."
How were Aegerion Pharmaceuticals' earnings last quarter?
Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) released its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.58) by $1.14. The biopharmaceutical company had revenue of $35.70 million for the quarter, compared to analyst estimates of $43 million. The company's quarterly revenue was down 39.9% on a year-over-year basis. During the same period last year, the firm posted ($0.55) earnings per share. View Aegerion Pharmaceuticals' Earnings History.
How do I buy shares of Aegerion Pharmaceuticals?
Shares of AEGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aegerion Pharmaceuticals' stock price today?
One share of AEGR stock can currently be purchased for approximately $1.97.
How big of a company is Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals has a market capitalization of $56.69 million. Aegerion Pharmaceuticals employs 318 workers across the globe.
What is Aegerion Pharmaceuticals' official website?
How can I contact Aegerion Pharmaceuticals?
Aegerion Pharmaceuticals' mailing address is 1 Main St Ste 800, CAMBRIDGE, MA 02142-1531, United States. The biopharmaceutical company can be reached via phone at +1-617-5007867.
MarketBeat Community Rating for Aegerion Pharmaceuticals (NASDAQ AEGR)
MarketBeat's community ratings are surveys of what our community members think about Aegerion Pharmaceuticals and other stocks. Vote "Outperform" if you believe AEGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEGR will underperform the S&P 500 over the long term. You may vote once every thirty days.
